MA49604B1 - Human antibodies binding to pd-1 - Google Patents
Human antibodies binding to pd-1Info
- Publication number
- MA49604B1 MA49604B1 MA49604A MA49604A MA49604B1 MA 49604 B1 MA49604 B1 MA 49604B1 MA 49604 A MA49604 A MA 49604A MA 49604 A MA49604 A MA 49604A MA 49604 B1 MA49604 B1 MA 49604B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- cell
- human antibodies
- binds
- bind
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des anticorps qui se lient à la protéine de mort cellulaire programmée-1 (pd-1) du co-inhibiteur de lymphocyte t, et des méthodes d'utilisation. Selon certains modes de réalisation de l'invention, les anticorps sont des anticorps complètement humains qui se lient à pd-1. Dans certains modes de réalisation, la présente invention concerne des molécules de liaison antigénique multi-spécifiques comprenant une première spécificité de liaison qui se lie à pd-1 et une seconde spécificité de liaison qui se lie à un antigène tissulaire auto-immun, un autre co-inhibiteur de lymphocyte t, un récepteur de fc ou un récepteur de lymphocyte t. Dans certains modes de réalisation, les anticorps de l'invention sont utilisés pour inhiber ou neutraliser l'activité de pd-1, ce qui fournit un moyen de traiter une maladie ou une affection comme le cancer ou une infection virale chronique. Dans d'autres modes de réalisation, les anticorps sont utilisés pour renforcer ou stimuler l'activité de pd-1, ce qui fournit un moyen de traiter, par exemple, une maladie ou une affection auto-immune.The present invention relates to antibodies that bind to t cell co-inhibitor programmed cell death protein-1 (pd-1), and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to pd-1. In some embodiments, the present invention relates to multi-specific antigen binding molecules comprising a first binding specificity that binds to pd-1 and a second binding specificity that binds to an autoimmune tissue antigen, another t-cell co-inhibitor, a fc receptor or a t-cell receptor. In certain embodiments, the antibodies of the invention are used to inhibit or neutralize the activity of pd-1, which provides a means of treating a disease or condition such as cancer or a chronic viral infection. In other embodiments, the antibodies are used to enhance or stimulate pd-1 activity, thereby providing a means of treating, for example, an autoimmune disease or condition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930576P | 2014-01-23 | 2014-01-23 | |
| PCT/US2015/012589 WO2015112800A1 (en) | 2014-01-23 | 2015-01-23 | Human antibodies to pd-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49604A1 MA49604A1 (en) | 2022-02-28 |
| MA49604B1 true MA49604B1 (en) | 2022-09-30 |
Family
ID=58698425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49604A MA49604B1 (en) | 2014-01-23 | 2015-01-23 | Human antibodies binding to pd-1 |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR099148A1 (en) |
| MA (1) | MA49604B1 (en) |
-
2015
- 2015-01-21 AR ARP150100162A patent/AR099148A1/en active IP Right Grant
- 2015-01-23 MA MA49604A patent/MA49604B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA49604A1 (en) | 2022-02-28 |
| AR099148A1 (en) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| MA40041B1 (en) | Anti-gitr antibodies and methods of use thereof | |
| MX2021009852A (en) | Human antibodies to pd-1. | |
| MA43461A1 (en) | Novel peptides, peptide combinations and carriers for use in the immunotherapeutic treatment of various cancers | |
| MA43328A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| MA44312A (en) | ANTIBODIES AND THEIR METHODS OF USE | |
| MA42935B1 (en) | Optimized anti-cd3 bispecific antibodies and their uses | |
| MA44101A (en) | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS | |
| MA43327A1 (en) | Peptides and peptide combination for use in immunotherapy against non-small cell lung cancer and other cancers | |
| RU2016143383A (en) | IMMUNOACTIVE ANTIGEN-BINDING MOLECULE | |
| MA40476B1 (en) | Antibodies and anti-lag3 antigen binding fragments | |
| MA37761A1 (en) | Proteins for binding to a double receptor antagonist antigen and their uses | |
| MA38161A1 (en) | Anti-bmp-6 Antibody | |
| EA200601972A1 (en) | ANTIBODIES TO INHIBITING ANGIOGENES DOMAINS CD148 | |
| MX2022014736A (en) | ANTI-CD200R1 ANTIBODIES AND METHODS OF USE OF THESE. | |
| MA49604B1 (en) | Human antibodies binding to pd-1 | |
| MA56083B1 (en) | HUMAN ANTIBODIES AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS MONOCLONAL PIC PROTEIN | |
| MA39202B1 (en) | Human antibodies against pd-l1 | |
| DK1730196T3 (en) | EphB4-binding antibodies to inhibit antiogenesis and tumor growth | |
| MA42523B1 (en) | Anti-psma antibodies, bispecific antigen-binding molecules which bind psma and cd3 and uses thereof | |
| MA37998B2 (en) | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses | |
| HK1228406A1 (en) | Human antibodies to pd-1 | |
| MA50374A (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
| MA38502A1 (en) | Isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds to human gremlin-1 useful for the treatment of fibrosis, cancers and inhibition of angiogenesis | |
| MA48870B1 (en) | Anti-sortilin antibodies and methods of their use |